HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Satisfied With Q2 Performance As Europe Returns to Growth

Executive Summary

GSK recorded gains in Europe and the US in Q2 as it ramped up preparations for the launch of its consumer health joint venture with Pfizer.

You may also be interested in...



GSK And Pfizer Agree To Divest ThermaCare To Win EU Approval For JV

GSK and Pfizer must find a buyer for the global rights to the ThermaCare pain relief brand to receive European Commission approval for their proposed joint venture.

Crown Grows With Keri From GSK, Which Says Little On Consumer Pending JV Launch With Pfizer

Sales to Crown Labs didn't breach GSK's attention when it reported its Q1 results, with its consumer health discussion limited to general figures on regions and product categories. Pfizer offered even less about its consumer health operations and plans with its Q1 report.For Crown Labs, landing North American rights to Keri brand marks another step toward offering comprehensive skin care selection.

Horlicks Brings Unilever 'Transformative' Nutritional Deal, Market Challenges

Firm's Hindustan Unilever division will merge with s GSK Consumer Healthcare India which has had total sales around €550m so far in 2018, primarily through the Horlicks and Boost brands and with nearly 90% of the revenues in India. Also will acquire 82% stake in GSK Bangladesh and other GSK commercial operations and assets outside India, paying €3.3bn in combination of cash and shares in Hindustan Unilever.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel